Literature DB >> 22123843

ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice.

Chintan Gandhi1, Mohammad Moshahid Khan, Steven R Lentz, Anil K Chauhan.   

Abstract

ADAMTS13, a metalloprotease, plays a pivotal role in preventing spontaneous microvascular thrombosis by cleaving hyperactive ultra large von Willebrand factor multimers into smaller, less active multimers. Reduced ADAMTS13 activity in plasma has been described in many diseases associated with systemic inflammation. It remains uncertain, however, whether ADAMTS13 contributes to disease pathogenesis or rather simply serves as an inflammation-associated marker. We hypothesized that, by decreasing vascular inflammation, ADAMTS13 reduces the development of early atherosclerotic plaques. Using intravital fluorescence microscopy, we observed excessive leukocyte adhesion and accelerated atherosclerotic plaque formation at the carotid sinus of Adamts13(-/-)/ApoE(-/-) mice compared with ApoE(-/-) mice fed a high-fat Western diet. At 4 months of age, there was a significant increase in atherosclerosis in the aorta and aortic sinus of Adamts13(-/-)/ApoE(-/-) mice compared with ApoE(-/-) mice. Interestingly, we detected a 2-fold increase in macrophage recruitment to the atherosclerotic plaque of the Adamts13(-/-)/ApoE(-/-) mice compared with ApoE(-/-) mice, suggesting that the atherosclerotic lesions in these mice were not only larger but also more inflammatory. These findings reveal a new functional role for the antithrombotic enzyme ADAMTS13 in reducing excessive vascular inflammation and plaque formation during early atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22123843      PMCID: PMC3311260          DOI: 10.1182/blood-2011-09-376202

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E.

Authors:  Yuqing Huo; Andreas Schober; S Bradley Forlow; David F Smith; Matthew Craig Hyman; Steffen Jung; Dan R Littman; Christian Weber; Klaus Ley
Journal:  Nat Med       Date:  2002-12-16       Impact factor: 53.440

2.  Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia.

Authors:  Gregor Theilmeier; Carine Michiels; Erik Spaepen; Ingrid Vreys; Désiré Collen; Jos Vermylen; Marc F Hoylaerts
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

3.  Changes in ADAMTS13 (von-Willebrand-factor-cleaving protease) activity after induced release of von Willebrand factor during acute systemic inflammation.

Authors:  Rosemarie A Reiter; Katalin Varadi; Peter L Turecek; Bernd Jilma; Paul Knöbl
Journal:  Thromb Haemost       Date:  2005-03       Impact factor: 5.249

4.  Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome.

Authors:  D B Rubin; J P Wiener-Kronish; J F Murray; D R Green; J Turner; J M Luce; A B Montgomery; J D Marks; M A Matthay
Journal:  J Clin Invest       Date:  1990-08       Impact factor: 14.808

5.  Effects of sex and age on atherosclerosis and autoimmunity in apoE-deficient mice.

Authors:  G Caligiuri; A Nicoletti; X Zhou; I Törnberg; G K Hansson
Journal:  Atherosclerosis       Date:  1999-08       Impact factor: 5.162

6.  von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively.

Authors:  L A Sporn; V J Marder; D D Wagner
Journal:  Blood       Date:  1987-05       Impact factor: 22.113

7.  Identification of strain-specific variants of mouse Adamts13 gene encoding von Willebrand factor-cleaving protease.

Authors:  Fumiaki Banno; Kazuyoshi Kaminaka; Kenji Soejima; Koichi Kokame; Toshiyuki Miyata
Journal:  J Biol Chem       Date:  2004-05-10       Impact factor: 5.157

8.  Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury.

Authors:  Lorraine B Ware; Mark D Eisner; B Taylor Thompson; Polly E Parsons; Michael A Matthay
Journal:  Am J Respir Crit Care Med       Date:  2004-06-16       Impact factor: 21.405

9.  Comparison of atherosclerotic lesions and HDL-lipid levels in male, female, and testosterone-treated female mice from strains C57BL/6, BALB/c, and C3H.

Authors:  B Paigen; P A Holmes; D Mitchell; D Albee
Journal:  Atherosclerosis       Date:  1987-04       Impact factor: 5.162

10.  A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation.

Authors:  Steffen Massberg; Korbinian Brand; Sabine Grüner; Sharon Page; Elke Müller; Iris Müller; Wolfgang Bergmeier; Thomas Richter; Michael Lorenz; Ildiko Konrad; Bernhard Nieswandt; Meinrad Gawaz
Journal:  J Exp Med       Date:  2002-10-07       Impact factor: 14.307

View more
  41 in total

Review 1.  Sex as a Biological Variable in Atherosclerosis.

Authors:  Joshua J Man; Joshua A Beckman; Iris Z Jaffe
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

2.  VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice.

Authors:  Alexander S Savchenko; Julian I Borissoff; Kimberly Martinod; Simon F De Meyer; Maureen Gallant; Luise Erpenbeck; Alexander Brill; Yanming Wang; Denisa D Wagner
Journal:  Blood       Date:  2013-11-07       Impact factor: 22.113

3.  Allosteric activation of ADAMTS13 by von Willebrand factor.

Authors:  Joshua Muia; Jian Zhu; Garima Gupta; Sandra L Haberichter; Kenneth D Friedman; Hendrik B Feys; Louis Deforche; Karen Vanhoorelbeke; Lisa A Westfield; Robyn Roth; Niraj Harish Tolia; John E Heuser; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

Review 4.  Platelets and von Willebrand factor in atherogenesis.

Authors:  Melinda D Wu; Tamara M Atkinson; Jonathan R Lindner
Journal:  Blood       Date:  2017-02-07       Impact factor: 22.113

5.  ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.

Authors:  Luise Erpenbeck; Melanie Demers; Zsuzsanna K Zsengellér; Maureen Gallant; Stephen M Cifuni; Isaac E Stillman; S Ananth Karumanchi; Denisa D Wagner
Journal:  J Am Soc Nephrol       Date:  2015-06-02       Impact factor: 10.121

6.  ADAMTS13 controls vascular remodeling by modifying VWF reactivity during stroke recovery.

Authors:  Haochen Xu; Yongliang Cao; Xing Yang; Ping Cai; Lijing Kang; Ximin Zhu; Haiyu Luo; Lu Lu; Lixiang Wei; Xiaofei Bai; Yuanbo Zhu; Bing-Qiao Zhao; Wenying Fan
Journal:  Blood       Date:  2017-04-20       Impact factor: 22.113

Review 7.  Structure-function and regulation of ADAMTS-13 protease.

Authors:  X L Zheng
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

Review 8.  ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

9.  Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura.

Authors:  Wenjing Cao; Huy P Pham; Lance A Williams; Jenny McDaniel; Rance C Siniard; Robin G Lorenz; Marisa B Marques; X Long Zheng
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

10.  Protective anti-inflammatory effect of ADAMTS13 on myocardial ischemia/reperfusion injury in mice.

Authors:  Simon F De Meyer; Alexander S Savchenko; Michael S Haas; Daphne Schatzberg; Michael C Carroll; Alexandra Schiviz; Barbara Dietrich; Hanspeter Rottensteiner; Friedrich Scheiflinger; Denisa D Wagner
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.